Pegaspargase: a review of clinical studies

Graham, Michael

doi:10.1016/s0169-409x(03)00110-8

Cited by 290 publications

(161 citation statements)

References 58 publications

Supporting

Mentioning

152

Contrasting

Unclassified

Order By: Relevance

“…Anti-thrombin III levels were not measured in the patient who died during the study; however, PT and aPTT were within normal limits upon her terminal admission and no lower extremity DVTs were noted on Doppler ultrasound ~1 week prior to her death. Other significant toxicities noted in our study, such as pancreatitis, fatigue, nausea, anorexia and a grade 3 allergic reaction, were consistent with those noted in previous studies (11,13,14). We would not recommend further investigation of pegaspargase in patients with advanced ovarian cancer, due to the incidence and severity of adverse effects in our study population.…”

Section: Grade (No Of Patients) ------------------------------------supporting

confidence: 93%

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety

Hays

Kim

Walker

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The anti-angiogenic activity of L-asparaginase (L-ASP) and the sensitivity of ovarian cancer cell lines to L-ASP has been previously demonstrated by preclinical findings. The aim of this clinical trial was to translate those findings and evaluate the activity of polyethylene glycol-conjugated L-asparaginase (PEG-ASP or pegaspargase) in advanced ovarian cancer. Women with recurrent ovarian cancer and good end-organ function were enrolled in an open-label phase II trial of PEG-ASP at a dose of 2,000 IU/m 2 by intravenous infusion every 2 weeks. Patients were evaluated for response every 8 weeks and for toxicity on an ongoing basis. Early stopping rules for toxicity and activity were included. Four patients were enrolled and received a total of 7 treatment cycles. The study ended accrual by invoking an early stopping rule, after excessive toxicity was identified in patients. Drug-related toxicities included grade 2 pancreatitis, fatigue, neutropenia, hypoalbuminemia, weight loss, dehydration, decreased fibrinogen and 1 case of grade 3 hypersensitivity reaction during cycle 2. One patient died during the study. No patients were evaluable for response. PEG-ASP was poorly tolerated in this group of advanced-stage ovarian cancer patients and no conclusions regarding activity may be drawn. Further studies of PEG-ASP in ovarian cancer patients are not recommended.

show abstract

Section: Grade (No Of Patients) ------------------------------------supporting

confidence: 93%

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety

Hays

Kim

Walker

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Examples of clinically used PEGylated proteins include PEG-asparaginase (43) (47). PEGylated nanomedicines include such examples as polyplex, a nanoparticle inhalation gene delivery system for gene therapy (48), stealth radiolabeled PEG 2K -liposomes and …”

Section: Discussionmentioning

confidence: 99%

Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies

Tung

Chen

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…There are two polymer-protein conjugates approved by the FDA up to date: the anti-tumor protein neocarzinostatin conjugated to styrene maleic anhydride (SMANCS or Zinostatin Stimalamer) that it is administered locally [97,98], and the PEG-protein conjugate, PEG-Lasparaginase (Pegaspargase or Oncaspar) that it is administered parenterally [99][100][101].…”

Section: Polymer Therapeuticsmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,383

754

View full text Add to dashboard Cite

Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vasculatization and, in time, adquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastasic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, like the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic Código de campo cambiado

show abstract

Pegaspargase: a review of clinical studies

Cited by 290 publications

References 58 publications

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety

Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Contact Info

Product

Resources

About